Study: A/C chemo takes toll on bones

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

The skeletal health of pre-menopausal women with estrogen receptor-negative breast cancer took a beating after six cycles of doxorubicin (Doxil)/cyclophosphamide (A/C) chemotherapy.

The skeletal health of pre-menopausal women with estrogen receptor-negative breast cancer took a beating after six cycles of doxorubicin (Doxil)/cyclophosphamide (A/C) chemotherapy.

Endocrinologists from Philipps University of Marburg, Germany compared bone mineral density, quantitative ultrasonography, and bone turnover markers in patients with age-matched controls (Eur J Cancer online, October 20, 2009).

They found that all patients became amenorrhoeic during and after chemotherapy. Patients had significant bone loss at all sites (P =.005) and significant increases in bone turnover (P = .05), the authors reported.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content